AR036191A1 - Compuestos antagonistas de receptores y5 del neuropeptido y, una composicion farmaceutica, un procedimiento para preparar dicha composicion y el uso de dichos compuestos, solos o en combinacion para la preparacion de una composicion farmaceutica - Google Patents
Compuestos antagonistas de receptores y5 del neuropeptido y, una composicion farmaceutica, un procedimiento para preparar dicha composicion y el uso de dichos compuestos, solos o en combinacion para la preparacion de una composicion farmaceuticaInfo
- Publication number
- AR036191A1 AR036191A1 ARP020102785A ARP020102785A AR036191A1 AR 036191 A1 AR036191 A1 AR 036191A1 AR P020102785 A ARP020102785 A AR P020102785A AR P020102785 A ARP020102785 A AR P020102785A AR 036191 A1 AR036191 A1 AR 036191A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- substituted alkyl
- hydrogen
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- -1 -NR5R6 Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 101710151321 Melanostatin Proteins 0.000 abstract 1
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 abstract 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 abstract 1
- 102000028582 Neuropeptide Y5 receptor Human genes 0.000 abstract 1
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto antagonista del receptor Y5 del neuropéptido Y, representado por la fórmula estructural (1) o una sal o solvato farmacéuticamente aceptable del mismo, en la cual: X es independientemente N ó C; Z es independientemente NR8 ó CR3R9; D es independientemente H, -OH, -alquilo o alquilo sustituido con la condición de que cuando X es N, D y el enlace X-D están ausentes; E es independientemente H, -alquilo o alquilo sustituido, o D y E pueden estar independientemente unidos conjuntamente a través de un puente -(CH2)p-; Q es independientemente H, -alquilo o alquilo sustituido, o D, X, Q y el carbono al cual Q se muestra adherido pueden formar conjuntamente un anillo de 3 a 7 miembros; g, j, k, m y n pueden ser iguales o diferentes y están independientemente seleccionados; g es 0 a 3 y cuando g es 0, los carbonos a los cuales está conectado (CH2)g no están ya ligados; j y k son independientemente 0 a 3 de manera que la suma de j y k es 0, 1, 2 ó 3; m y n son independientemente 0 a 3 de manera que la suma de m y n es 1, 2, 3, 4 ó 5; p es 1 a 3; R1 es 1 a 5 sustituyentes que pueden ser iguales o diferentes, estando cada R1 independientemente seleccionado del grupo que consiste en hidrógeno, hidroxi, halógeno, haloalquilo, -alquilo, alquilo sustituido, -cicloalquilo, CN, alcoxi, cicloalcoxi, alquiltio, cicloalquiltio, -NR5R6, -NO2, -CONR5R6, -NR5COR6, -NR5CONR5R9 donde las dos porciones R5 pueden ser iguales o diferentes, -NR6C(O)OR7, -C(O)OR6, -SOR7, -SO2R7, -SO2NR5R6, arilo y heteroarilo; R2 es 1 a 6 sustituyentes que pueden ser iguales o diferentes, estando cada R2 independientemente seleccionado del grupo que consiste en hidrógeno, -alquilo, alquilo sustituido, alcoxi, e hidroxi, con la condición de que cuando X es N y R2 es hidroxi o alcoxi, R2 no está directamente adherido a un carbono adyacente a X; R3 es independientemente hidrógeno, alquilo o alquilo sustituido; R4 es 1 a 6 sustituyentes que pueden ser iguales o diferentes, estando cada R4 independientemente seleccionado entre hidrógeno, -alquilo, alquilo sustituido, alcoxi, e hidroxi, con la condición de que cuando Z es NR8 y R4 es hidroxi o alcoxi, R4 no está directamente adherido a un carbono adyacente al NR8; R5 y R6 son independientemente hidrógeno, -alquilo, alquilo sustituido o -cicloalquilo; R7 es independientemente -alquilo, alquilo sustituido o -cicloalquilo; R8 está independientemente seleccionado del grupo que consiste en hidrógeno, -alquilo, alquilo sustituido, -cicloalquilo, -alquilcicloalquilo, arilo, heteroarilo, aralquilo, heteroaralquilo, -SO2R10, -SO2NR5R11, -C(O)R11, -C(O)NR5R11 y -C(O)OR10; R9 es independientemente hidrógeno, -alquilo, alquilo sustituido, hidroxi, alcoxi, -NR5R11, arilo o heteroarilo; o R3 y R9 pueden estar unidos conjuntamente y con el carbono al cual están unidos forman un anillo carbocíclico o heterocíclico que tiene 3 a 7 átomos en el anillo; R10 es -alquilo, alquilo sustituido, -cicloalquilo, -alquilcicloalquilo, arilo o heteroarilo; y R11 es independientemente hidrógeno, -alquilo, alquilo sustituido, -cicloalquilo, arilo o heteroarilo. En otra realización, se describen composiciones farmacéuticas que comprenden dichos antagonistas receptores Y5 de NPY, un procedimiento para su preparación, así como también los usos de dichos compuestos, sólos o en combinación para preparar una composición farmacéutica para tratar obesidad, desórdenes metabólicos, desórdenes de la alimentación tales como hiperfagia y diabetes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30843301P | 2001-07-26 | 2001-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036191A1 true AR036191A1 (es) | 2004-08-18 |
Family
ID=23193972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102785A AR036191A1 (es) | 2001-07-26 | 2002-07-24 | Compuestos antagonistas de receptores y5 del neuropeptido y, una composicion farmaceutica, un procedimiento para preparar dicha composicion y el uso de dichos compuestos, solos o en combinacion para la preparacion de una composicion farmaceutica |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6667319B2 (es) |
| EP (1) | EP1418913A1 (es) |
| JP (1) | JP2005500338A (es) |
| CN (2) | CN1911913A (es) |
| AR (1) | AR036191A1 (es) |
| AU (1) | AU2002355286B2 (es) |
| CA (1) | CA2454830C (es) |
| HU (1) | HUP0401643A3 (es) |
| IL (1) | IL159643A0 (es) |
| IS (1) | IS7096A (es) |
| MX (1) | MXPA04000707A (es) |
| NZ (1) | NZ530429A (es) |
| PE (1) | PE20030385A1 (es) |
| PL (1) | PL368201A1 (es) |
| TW (1) | TWI300064B (es) |
| WO (1) | WO2003009845A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| ES2320979T3 (es) * | 2001-09-24 | 2009-06-01 | Imperial Innovations Limited | Pyy-36 para la reduccion o prevencion de la obesidad. |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2520763A1 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| JP2008517072A (ja) | 2004-10-20 | 2008-05-22 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良された阻害剤 |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| CA2613236A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
| FR2894964B1 (fr) * | 2005-12-19 | 2008-02-22 | Cerep Sa | Composes a base de quatre cycles aromatiques, preparation et utilisations |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| EP2058305A4 (en) | 2006-08-30 | 2010-09-22 | Shionogi & Co | UREA DERIVATIVE |
| TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
| US9296693B2 (en) | 2010-01-29 | 2016-03-29 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
| CN102675190A (zh) * | 2012-05-23 | 2012-09-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种3-（二甲氨基）次甲基-n-甲磺酰基哌啶-4-酮的合成方法 |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP2958562B1 (en) | 2013-02-22 | 2025-09-10 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| RS65632B1 (sr) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Ltd | Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CN111787916B (zh) | 2018-01-11 | 2023-09-05 | 森陶鲁斯治疗公司 | 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂 |
| WO2022076365A1 (en) * | 2020-10-06 | 2022-04-14 | Eastman Chemical Company | Aromatic enol ethers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| IL139913A0 (en) | 1998-06-08 | 2002-02-10 | Schering Corp | Neuropeptide y5 receptor antagonists |
| CA2350714A1 (en) | 1998-11-10 | 2000-05-18 | Merck & Co., Inc. | Spiro-indolines as y5 receptor antagonists |
| US20020165223A1 (en) * | 2000-09-14 | 2002-11-07 | Greenlee William J. | Substituted urea neuropeptide Y Y5 receptor antagonists |
-
2002
- 2002-07-24 TW TW091116480A patent/TWI300064B/zh active
- 2002-07-24 HU HU0401643A patent/HUP0401643A3/hu unknown
- 2002-07-24 AR ARP020102785A patent/AR036191A1/es unknown
- 2002-07-24 AU AU2002355286A patent/AU2002355286B2/en not_active Ceased
- 2002-07-24 NZ NZ530429A patent/NZ530429A/en unknown
- 2002-07-24 PL PL02368201A patent/PL368201A1/xx not_active Application Discontinuation
- 2002-07-24 EP EP02752562A patent/EP1418913A1/en not_active Withdrawn
- 2002-07-24 US US10/202,239 patent/US6667319B2/en not_active Expired - Fee Related
- 2002-07-24 CN CNA2006101215468A patent/CN1911913A/zh active Pending
- 2002-07-24 MX MXPA04000707A patent/MXPA04000707A/es active IP Right Grant
- 2002-07-24 CN CNA028189647A patent/CN1558764A/zh active Pending
- 2002-07-24 PE PE2002000653A patent/PE20030385A1/es not_active Application Discontinuation
- 2002-07-24 CA CA002454830A patent/CA2454830C/en not_active Expired - Fee Related
- 2002-07-24 IL IL15964302A patent/IL159643A0/xx unknown
- 2002-07-24 JP JP2003515237A patent/JP2005500338A/ja active Pending
- 2002-07-24 WO PCT/US2002/023552 patent/WO2003009845A1/en not_active Ceased
-
2003
- 2003-10-24 US US10/692,559 patent/US7304076B2/en not_active Expired - Fee Related
- 2003-12-31 IS IS7096A patent/IS7096A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ530429A (en) | 2005-09-30 |
| HUP0401643A3 (en) | 2009-06-29 |
| US20030207860A1 (en) | 2003-11-06 |
| US20040102474A1 (en) | 2004-05-27 |
| CN1911913A (zh) | 2007-02-14 |
| MXPA04000707A (es) | 2004-04-20 |
| CA2454830C (en) | 2010-02-02 |
| US7304076B2 (en) | 2007-12-04 |
| TWI300064B (en) | 2008-08-21 |
| AU2002355286B2 (en) | 2005-10-13 |
| CA2454830A1 (en) | 2003-02-06 |
| IL159643A0 (en) | 2004-06-01 |
| CN1558764A (zh) | 2004-12-29 |
| JP2005500338A (ja) | 2005-01-06 |
| WO2003009845A9 (en) | 2004-03-11 |
| HUP0401643A2 (hu) | 2004-12-28 |
| WO2003009845A1 (en) | 2003-02-06 |
| US6667319B2 (en) | 2003-12-23 |
| IS7096A (is) | 2003-12-31 |
| EP1418913A1 (en) | 2004-05-19 |
| PE20030385A1 (es) | 2003-05-08 |
| PL368201A1 (en) | 2005-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036191A1 (es) | Compuestos antagonistas de receptores y5 del neuropeptido y, una composicion farmaceutica, un procedimiento para preparar dicha composicion y el uso de dichos compuestos, solos o en combinacion para la preparacion de una composicion farmaceutica | |
| AR046272A1 (es) | Inhibidores de dipeptidil peptidasa iv | |
| UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
| AR037243A1 (es) | Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento | |
| AR036596A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1 | |
| AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
| AR048523A1 (es) | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos | |
| BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso | |
| AR048266A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende y su uso para prepararla | |
| AR035783A1 (es) | Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3 | |
| RU2005134230A (ru) | Ацилированные производные спиропиперидина как агонисты рецептора меланокортина-4 | |
| AR061222A1 (es) | Derivados de 2-oxo-piridina, 2-oxo-quinolina y 2-oxo-isoquinolina, composiciones farmaceuticas que los comprenden y el uso de los mismos en medicamentos para tratar enfermedades mediadas por la scd. | |
| UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
| AR063147A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central. | |
| PE20070431A1 (es) | Compuestos y composiciones de carboxamidas sustituidas como moduladores de receptores cannabinoides | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
| MA29498B1 (fr) | Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1 | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| DE602004027409D1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
| AR044662A1 (es) | Compuestos de azetidina | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR050274A1 (es) | Derivados triciclicos del indeno-pirrol como moduladores de la serotonina | |
| AR046967A1 (es) | Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| AR032134A1 (es) | Compuestos derivados de propilo tienoisoxazolil- y tienilpirrazolil-fenoxi-substituidos utiles como antagonistas d4, composiciones farmaceuticas, procedimientos de preparacion, compuestos intermediarios y usos en la fabricacion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |